Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.70 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR1E | P28566 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842075 | 0.84 | PDE4D (0.48) | HTR7 | |
| Hydrochloric Acid SCHEMBL3843716 | 0.83 | PDE4D (0.47) | HTR7NOS1 | |
| SCHEMBL3786457 | 0.81 | HTR7 (0.45) | HTR7 | |
| SCHEMBL3789262 | 0.80 | FYN (0.51) | — | |
| SCHEMBL3838036 | 0.78 | HTR7 (0.62) | HTR7ACHE | |
| SCHEMBL3842196 | 0.77 | CASR (0.52) | HTR7 | |
| SCHEMBL6259929 | 0.76 | CYP3A4 (0.56) | — | |
| SCHEMBL14100109 | 0.76 | TAAR1 (0.56) | HTR7NOS1 | |
| SCHEMBL654302 | 0.75 | PTGDR2 (0.57) | — | |
| SCHEMBL3841461 | 0.75 | PDE4D (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| EP-1641465-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005025555-A2 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | HTR7 117/4885HTR1A 184/4885HTR1D 240/4885 |
| US-20030229058-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | HTR7 141/4885HTR1A 136/4885HTR1D 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.